EOM613
Inflammatory Conditions (COVID-19, Cancer Cachexia, Rheumatoid Arthritis)
Phase 1/2Active
Key Facts
Indication
Inflammatory Conditions (COVID-19, Cancer Cachexia, Rheumatoid Arthritis)
Phase
Phase 1/2
Status
Active
Company
About EOM Pharmaceuticals
EOM Pharmaceuticals is a clinical-stage biotech focused on developing novel therapies for inflammatory and retinal diseases. Its core strategy leverages a unique peptide-nucleic acid (PNA) platform, exemplified by lead candidate EOM613, which aims to dynamically modulate the immune system to address cytokine-driven pathologies. The company has advanced EOM613 into Phase 1/2 clinical testing in COVID-19 and is developing a second asset, EOM147, as a topical eye drop for retinal diseases. EOM's mission is to 'rescue, repair, and restore health' by transforming therapeutic paradigms in areas of high unmet need.
View full company profile